The invention discloses a chimeric antigen receptor T lymphocyte and its application in preparing products for treating solid tumors. The chimeric antigen receptors in the chimeric antigen receptor T lymphocytes sequentially include human CD8 leader peptide, anti-Siglec-15 single-chain antibody, human CD8 hinge transmembrane region, human 4-1BB intracellular region, human CD3ζ cell Inner region, self-cleaving peptide, CSF2Ra signal peptide, EGFRt protein, self-cleaving peptide and human CD27. It is proved by experiments that the chimeric antigen receptor T lymphocytes of the present invention highly express IFNγ and CD107a, have a strong killing function on Siglec-15 positive tumor cells, and the killing efficiency exceeds 1 when the effect-target ratio is 1:1. 80%. Tumor transplantation model experiments show that the chimeric antigen receptor T lymphocytes of the present invention also have a strong killing function against Siglec‑15 positive tumor cells in animals.